Numb and its alternative splicing in pancreatic cancer

Penghao LI; Kailian ZHENG; Xiongfei XU; Gang JIN

doi:10.3969/j.issn.1001-5256.2022.12.042

Volume 38 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(12): 2897-2900

PDF( 1884 KB)

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Department of Hepatobiliary Pancreatic and Splenic Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Research funding:

Natural Science Fund project of Shanghai 2020 "Science and Technology Innovation Action Plan" (20ZR1457300)

More Information

Corresponding author: ZHENG Kailian, zhengkl828@126.com (ORCID: 0000-0002-7341-0639)
Received Date: 2022-06-01
Accepted Date: 2022-07-22
Published Date: 2022-12-20

Abstract

Abstract

Pancreatic cancer, a common digestive system tumor with high malignancy and a poor prognosis, has several treatment options. However, none of them are particularly effective because understanding the pathogenesis of pancreatic cancer remains a significant clinical challenge. Splicing isoforms mediate various biological phenotypes as an important means of regulating gene expression in eukaryotes, and their abnormalities can lead to a variety of diseases. Numb is an important cell fate determining protein whose alternative splicing has been linked to the development of various cancers. In pancreatic cancer, selective splicing of Numb can result in a variety of Numb protein subtypes, each with a different regulatory effect on the activation of various cancer-related signal pathways and tumor cell biology. This paper reviews the recent progress of Numb protein research in pancreatic cancer, with a focus on the regulatory role of its different isoforms in pathogenesis.
- Pancreatic Neoplasms,
- Numb,
- Spliceosomes

FullText(HTML)

References(43)

References

[1]	MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/S0140-6736(20)30974-0.
[2]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. DOI: 10.3322/caac.21442.
[3]	GULINO A, DI MARCOTULLIO L, SCREPANTI I. The multiple functions of Numb[J]. Exp Cell Res, 2010, 316(6): 900-906. DOI: 10.1016/j.yexcr.2009.11.017.
[4]	WESTHOFF B, COLALUCA IN, D'ARIO G, et al. Alterations of the Notch pathway in lung cancer[J]. Proc Natl Acad Sci U S A, 2009, 106(52): 22293-22298. DOI: 10.1073/pnas.0907781106.
[5]	LU Y, XU W, JI J, et al. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma[J]. Hepatology, 2015, 62(4): 1122-1131. DOI: 10.1002/hep.27923.
[6]	PECE S, SERRESI M, SANTOLINI E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis[J]. J Cell Biol, 2004, 167(2): 215-221. DOI: 10.1083/jcb.200406140.
[7]	ZHENG KL, HE TL, JI WP, et al. Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(6): 6181-6191.
[8]	SHENG W, DONG M, ZHOU J, et al. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer[J]. Cell Tissue Res, 2013, 354(2): 521-532. DOI: 10.1007/s00441-013-1679-6.
[9]	BECHARA EG, SEBESTYÉN E, BERNARDIS I, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation[J]. Mol Cell, 2013, 52(5): 720-733. DOI: 10.1016/j.molcel.2013.11.010.
[10]	CHOI HY, SEOK J, KANG GH, et al. The role of NUMB/NUMB isoforms in cancer stem cells[J]. BMB Rep, 2021, 54(7): 335-343. DOI: 10.5483/BMBRep.
[11]	MCGILL MA, DHO SE, WEINMASTER G, et al. Numb regulates post-endocytic trafficking and degradation of Notch1[J]. J Biol Chem, 2009, 284(39): 26427-26438. DOI: 10.1074/jbc.M109.014845.
[12]	WANG C, NING K, HU HH, et al. Research progress in tumor microenvironment of pancreatic cancer[J]. Chin J Dig Surg, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018. 王超, 宁克, 胡欢欢, 等. 胰腺癌肿瘤微环境的研究进展[J]. 中华消化外科杂志, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018.
[13]	NATSUIZAKA M, WHELAN KA, KAGAWA S, et al. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma[J]. Nat Commun, 2017, 8(1): 1758. DOI: 10.1038/s41467-017-01500-9.
[14]	COUTURIER L, MAZOUNI K, SCHWEISGUTH F. Numb localizes at endosomes and controls the endosomal sorting of notch after asymmetric division in Drosophila[J]. Curr Biol, 2013, 23(7): 588-593. DOI: 10.1016/j.cub.2013.03.002.
[15]	COUTURIER L, MAZOUNI K, SCHWEISGUTH F. Inhibition of Notch recycling by Numb: relevance and mechanism(s)[J]. Cell Cycle, 2013, 12(11): 1647-1648. DOI: 10.4161/cc.24983.
[16]	FRISE E, KNOBLICH JA, YOUNGER-SHEPHERD S, et al. The Drosophila Numb protein inhibits signaling of the Notch receptor during cell-cell interaction in sensory organ lineage[J]. Proc Natl Acad Sci U S A, 1996, 93(21): 11925-11932. DOI: 10.1073/pnas.93.21.11925.
[17]	MCGILL MA, MCGLADE CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain[J]. J Biol Chem, 2003, 278(25): 23196-23203. DOI: 10.1074/jbc.M302827200.
[18]	MISQUITTA-ALI CM, CHENG E, O'HANLON D, et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer[J]. Mol Cell Biol, 2011, 31(1): 138-150. DOI: 10.1128/MCB.00709-10.
[19]	GVNGÖR C, HOFMANN BT, WOLTERS-EISFELD G, et al. Pancreatic cancer[J]. Br J Pharmacol, 2014, 171(4): 849-858. DOI: 10.1111/bph.12401.
[20]	BARMAN S, FATIMA I, SINGH AB, et al. Pancreatic cancer and therapy: Role and regulation of cancer stem cells[J]. Int J Mol Sci, 2021, 22(9): 4765. DOI: 10.3390/ijms22094765
[21]	TRUONG LH, PAUKLIN S. Pancreatic cancer microenvironment and cellular composition: Current understandings and therapeutic approaches[J]. Cancers (Basel), 2021, 13(19): 5028. DOI: 10.3390/cancers13195028.
[22]	YANG L, SHI P, ZHAO G, et al. Targeting cancer stem cell pathways for cancer therapy[J]. Signal Transduct Target Ther, 2020, 5(1): 8. DOI: 10.1038/s41392-020-0110-5.
[23]	NWAEBURU CC, ABUKIWAN A, ZHAO Z, et al. Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer[J]. Mol Cancer, 2017, 16(1): 23. DOI: 10.1186/s12943-017-0589-8.
[24]	LUU T. Epithelial-mesenchymal transition and its regulation mechanisms in pancreatic cancer[J]. Front Oncol, 2021, 11: 646399. DOI: 10.3389/fonc.2021.646399.
[25]	DONGRE A, WEINBERG RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84. DOI: 10.1038/s41580-018-0080-4.
[26]	GAIANIGO N, MELISI D, CARBONE C. EMT and treatment resistance in pancreatic cancer[J]. Cancers (Basel), 2017, 9(9): 122. DOI: 10.3390/cancers9090122.
[27]	PAN G, LIU Y, SHANG L, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun (Lond), 2021, 41(3): 199-217. DOI: 10.1002/cac2.12138.
[28]	SHENG WW, DONG M, LIU ZR, et al. Relationship and clinicopathological significance of Numb and epithelial-mesenchymal transition related proteins in human pancreatic cancer[J]. Chin J Surg, 2016, 54(12): 929-934. DOI: 10.3760/cma.j.issn.0529-5815.2016.12.011. 盛伟伟, 董明, 刘峥嵘, 等. Numb与上皮细胞间质转分化相关蛋白在胰腺癌中表达的相关性及其临床病理学意义[J]. 中华外科杂志, 2016, 54(12): 929-934. DOI: 10.3760/cma.j.issn.0529-5815.2016.12.011.
[29]	SHENG W, TANG J, CAO R, et al. Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer[J]. Cell Death Dis, 2022, 13(2): 173. DOI: 10.1038/s41419-022-04609-y.
[30]	KRUSE JP, GU W. Modes of p53 regulation[J]. Cell, 2009, 137(4): 609-622. DOI: 10.1016/j.cell.2009.04.050.
[31]	HU J, CAO J, TOPATANA W, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies[J]. J Hematol Oncol, 2021, 14(1): 157. DOI: 10.1186/s13045-021-01169-0.
[32]	BYKOV V, ERIKSSON SE, BIANCHI J, et al. Targeting mutant p53 for efficient cancer therapy[J]. Nat Rev Cancer, 2018, 18(2): 89-102. DOI: 10.1038/nrc.2017.109.
[33]	TOSONI D, ZECCHINI S, COAZZOLI M, et al. The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells[J]. J Cell Biol, 2015, 211(4): 845-862. DOI: 10.1083/jcb.201505037.
[34]	CONFALONIERI S, COLALUCA IN, BASILE A, et al. Exon 3 of the NUMB gene emerged in the chordate lineage coopting the NUMB protein to the regulation of MDM2[J]. G3 (Bethesda), 2019, 9(10): 3359-3367. DOI: 10.1534/g3.119.400494.
[35]	COLALUCA IN, BASILE A, FREIBURGER L, et al. A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer[J]. J Cell Biol, 2018, 217(2): 745-762. DOI: 10.1083/jcb.201709092.
[36]	NEOPTOLEMOS JP, KLEEFF J, MICHL P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 333-348. DOI: 10.1038/s41575-018-0005-x.
[37]	ZHANG TP, LIU RZ, REN B. Current status and challenges of total neoadjuvant therapy for pancreatic cancer[J]. Chin J Dig Surg, 2022, 21(4): 461-464. DOI: 10.3760/cma.j.cn115610-20220320-00141. 张太平, 刘悦泽, 任博. 胰腺癌全程新辅助治疗的现状及挑战[J]. 中华消化外科杂志, 2022, 21(4): 461-464. DOI: 10.3760/cma.j.cn115610-20220320-00141.
[38]	HO WJ, JAFFEE EM, ZHENG L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540. DOI: 10.1038/s41571-020-0363-5.
[39]	ZENG S, PÖTTLER M, LAN B, et al. Chemoresistance in pancreatic cancer[J]. Int J Mol Sci, 2019, 20(18): 4504. DOI: 10.3390/ijms20184504.
[40]	HENG W, DONG M, CHEN C, et al. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer[J]. FASEB J, 2017, 31(6): 2429-2438. DOI: 10.1096/fj.201601240R.
[41]	SESHACHARYULU P, BAINE MJ, SOUCHEK JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868(1): 69-92. DOI: 10.1016/j.bbcan.2017.02.003.
[42]	RAJASEKAR P, O'NEILL CL, EELES L, et al. Epigenetic changes in endothelial progenitors as a possible cellular basis for glycemic memory in diabetic vascular complications[J]. J Diabetes Res, 2015, 2015: 436879. DOI: 10.1155/2015/436879.
[43]	ZHU D, XIA J, LIU C, et al. Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin[J]. Cell Signal, 2022, 93: 110268. DOI: 10.1016/j.cellsig.2022.110268.

Relative Articles

[1]	Daqing LIU, Yan HUANG, Jianhe GAN. Value of serum creatinine-to-cystatin C ratio in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 264-270. doi: 10.12449/JCH240208
[2]	Wei JIANG, Xiujun CHANG, Fan ZENG, Yunping LAN. Current status of research on artificial intelligence in prognostic prediction models for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(9): 1891-1896. doi: 10.12449/JCH240927
[3]	Wenling LUO, Yu ZENG, Xuemei ZHANG, Yunjian SHENG. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(10): 1985-1991. doi: 10.12449/JCH241010
[4]	Yuqi CHEN, Chunyan LI, Shanhong TANG. Value of Δtotal bilirubin-alpha-fetoprotein scoring model in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(12): 2399-2405. doi: 10.12449/JCH241209
[5]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[6]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[7]	Jiang LI, Xing DAI, Dazhi TIAN, Wentao JIANG, Zhongyang SHEN. Advances in the clinical research on liver transplantation in treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1188-1191. doi: 10.3969/j.issn.1001-5256.2022.05.045
[8]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[9]	Xinyi GAO, Li CHEN, Jianhe GAN. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(5): 1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019
[10]	Jing GU, Yan WANG, Wei SUN, Weifeng ZHAO, Jianhe GAN. Value of interleukin-32 combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(2): 304-308. doi: 10.3969/j.issn.1001-5256.2021.02.012
[11]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[12]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[13]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[14]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[15]	Li Chen, Tan JunYuan, Xu Xiang. Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1960-1965. doi: 10.3969/j.issn.1001-5256.2020.09.010
[16]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[17]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023
[18]	Dou HongLian, He HongYan, Xiao CiJun, Wang Bo, Li Ye, Sheng YunJian, Deng CunLiang. Value of indocyanine green clearance test in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(12): 2759-2764. doi: 10.3969/j.issn.1001-5256.2019.12.024
[19]	Liu JingHua, Liu Na, Liu ChenXi. Clinical value of indocyanine green retention rate in condition analysis and prognostic evaluation of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(11): 2155-2158. doi: 10.3969/j.issn.1001-5256.2016.11.031
[20]	Ma ChunHua, Chen Yu, Chen ChengWei, Ni LiuDa, Duan ZhongPing. Prognostic value of indocyanine green and liver reserve function in acute and acute-on-chronic liver failure patients[J]. Journal of Clinical Hepatology, 2012, 28(5): 372-375.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1496) PDF downloads(36)

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content